There were two further phase IIa studies evaluating cotadutide with the first one showing that it reduced glucose levels in those with obesity and T2DM with the mechanism being greater insulin secretion and delayed gastric emptying [46]
GLP-1 receptor agonists are positioned as one of the pharmacotherapeutic options that can contribute to addressing the high unmet medical need characterizing several prevalent aging-related diseases, making them ideal for our longevity-focused approach
For instance, in SUSTAIN-7, semaglutide 0.5 mg and 1.0 mg were compared to dulaglutide 0.75 mg and 1.5 mg: semaglutide resulted in significantly greater A1c reduction (1.5% vs 1.1% at highest doses) ( [6] )
In 2020, FDA granted fast track designation to efocipegtrutide for the treatment of nonalcoholic steatohepatitis (NASH), the most severe form of NAFLD
Although tirzepatide has not demonstrated anabolic bone actions in animals, 57 an assessment report from the European Medicine Agency observed trends of decreased P1NP and increased CTX-I levels in people with T2D after 29 days of treatment
GLP-1 Therapy May Help With Increased appetite linked to metabolic imbalance Persistent cravings that disrupt healthy routines Difficulty losing weight despite regular diet and exercise Metabolic concerns associated with insulin resistance Overeating tied to disrupted hunger and fullness cues Testimonials Best place for weight loss options
